ArticlePloS one2025
Analysis of the efficacy of splenic artery superselective embolization in cirrhosis with hepatocellular carcinoma.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Longitudinal Inpatient Trajectories After Splenic Artery Embolization in Cirrhosis: Real-World Evidence from Kazakhstan.Journal of clinical medicine · 2026Article
- Partial splenic embolization plus antitumor therapy for treating patients with hepatocellular carcinoma and splenomegaly: a case series study.Journal of gastrointestinal oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo explore the safety and effectiveness of partial splenic embolization (PSE) in patients with hypersplenism and hepatocellular carcinoma (HCC) and to compare the efficacy of superselective and non-superselective embolization of splenic artery branches. PROCEDURE: We retrospectively analyzed 64 patients with HCC who underwent PSE between August 2020 and December 2022. The patients were categorized into two groups based on different treatment plans: Group A (n=33) underwent superselective embolization and Group B (n=31) underwent non-superselective embolization of the splenic artery branches. The safety and effectiveness of the two methods were evaluated along with changes in peripheral blood cells [mainly white blood cells (WBC) and red blood cells (RBC)] and platelet (PLT) counts at different time points after PSE. Postoperative adverse events were also compared between the two groups.
resultsThe technical success rate was 100% for both procedures. The PLT and WBC counts of the two groups significantly increased one week after PSE (P<0.05), and there was no statistically significant difference in the RBC count changes. At follow-up (4, 16, and 24 weeks), the PLT and WBC counts remained consistent at levels which were significantly different from those before PSE (P<0.05). However, the RBC counts were not significantly different (P>0.05). An independent sample t-test was used to compare the differences in blood counts between the two groups at the same time point. There were no statistically significant differences in PLT, WBC, and RBC counts between Group A and Group B at any time point after PSE (P>0.05). The incidence of fever and pain in Group B was significantly higher than that in Group A (P<0.05).
conclusionPartial splenic artery embolization is a safe and effective treatment option for hypersplenism. Both splenic artery branch superselective and non-superselective embolization strategies demonstrated comparable outcomes. However, superselective embolization exhibited a lower incidence of postprocedural complications than non-superselective embolization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.